• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Sitemap

Sitemap EUCAST - Home About EUCAST Organisation Steering Committee General Committee EUCAST Statutes National AST Committees (NAC) Network Laboratories Development Laboratories (EDL) Subcommittees Antimycobacterial Susceptibility Testing (AMST) Antifungal Susceptibility Testing (AFST) Veterinary…

Get to know more

Breakpoints for Rapid AST

Breakpoints for Rapid AST Breakpoints validated for EUCAST short incubation disk diffusion directly from positive blood culture bottles. For interpretation of rapid AST directly from blood culture bottles, reading and interpreting inhibition zones after 4 hours, 6 hours, 8 hours and 16-20 hours,…

Get to know more

About Clinical Breakpoints

About Clinical Breakpoint Tables Clinical breakpoints are for everyday use to advise on patient therapy. Breakpoint tables are updated on the 1st of January each year. Tentative new tables are published in early December - this is for consultation and to permit laboratories to prepare for changes.…

Get to know more

When there are no breakpoints?

When there are no breakpoints? When there are no breakpoints? Guidance document, 29 September 2024 Download PDF Sometimes breakpoints for a species and/or an agent are lacking in EUCAST tables. This may happen because data to allow setting breakpoints is lacking, especially for rare species;…

Get to know more

Public Consultations

Public Consultations Public consultation is part of the EUCAST decision process. The consultation period is 4 - 12 weeks, and the dates of the beginning and end of the period is clearly stated. Current public consultations Subject Dates Description Carbapenem susceptibility testing and reporting -…

Get to know more

Document Archive

Document Archive Breakpoint tables QC tables Guidance documents Expert rules Rationale documents Disk diffusion methodology Disk diffusion validation RAST Expected phenotypes Broth microdilution Clinical breakpoints (v 14.0) - file for printing (1 Jan, 2024 - 31 Dec 2024) Clinical breakpoints (v…

Get to know more

Development of Clinical Breakpoints and ECOFFs

Development of Clinical Breakpoints and ECOFFs These pages collate information on the definition of clinical breakpoints and the process of setting MIC breakpoints. Background information is given in the Rationale Documents and in Public Consultations and the MIC:ZD (MIC vs. zone diameter)…

Get to know more

Clinical Breakpoint Tables

Clinical Breakpoint Tables Breakpoints are part of a system for categorizing microorganisms as: Susceptible (S) Susceptible, increased exposure (I) Resistant (R) To antimicrobial agents approved for use in the treatment of infectious diseases. Information of the structure of the tables and how they…

Get to know more

Setting Breakpoints

Setting Breakpoints Breakpoints for phenotypic antimicrobial susceptibility testing have been determined by breakpoint committees and as part of regulatory processes for the approval of new drugs since the 1970s. Knowledge of dosage, modes of administration, target infections and clinical outcome…

Get to know more

Clinical breakpoint table

Clinical breakpoint table (Yeast and moulds) Breakpoints and methods for susceptibility testing of yeasts, moulds and dermatophytes are developed and validated by the EUCAST subcommittee on AFST. Document Description Clinical breakpoints for fungi v. 12.0 PDF file for printing; valid from 26 June,…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here